OSTEOMARK NTX POINT OF CARE PRESCRIPTION HOME USE— 510(k) K011052

Substantially Equivalent

Ostex Intl., Inc.

FDA 510(k) clearance K011052 for OSTEOMARK NTX POINT OF CARE PRESCRIPTION HOME USE, Substantially Equivalent on 2001-07-30. Applicant: Ostex Intl., Inc..

Clearance details

Applicant
Ostex Intl., Inc.
Product code
Code JMM
Advisory panel
Clinical Chemistry
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Traditional
Location
Seattle, WA, US
Download summary PDFView on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.